Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Gopal on the Nuances of IO/TKI Selection in Advanced RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the nuances of treatment decision-making in advanced renal cell carcinoma.

Dr Gopal on the Evolution of TKI/IO Combination Approaches in RCC

March 7th 2024

Nikhil A. Gopal, MD, discusses the transition of treatment with TKIs to treatment with TKI/IO combinations for those with renal cell carcinoma.

Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Neoadjuvant Tislelizumab Plus Axitinib Generates Responses in Locally Advanced ccRCC

March 2nd 2024

Neoadjuvant tislelizumab plus axitinib demonstrated clinical efficacy and safety in patients with nonmetastatic clear cell renal cell carcinoma.

Recent Subgroup Analyses from the CLEAR study in Advanced RCC

March 1st 2024

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

March 1st 2024

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

Dr Rini on the Utility of Belzutifan in RCC

March 1st 2024

Brian I. Rini, MD, FASCO, discusses the background that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Belzutifan Regimens Show Promise in RCC as Frontline IO/TKI Armamentarium Expands

February 28th 2024

Nikhil A. Gopal, MD, discusses the benefit of belzutifan in addition to effective immunotherapy-based regimens in advanced RCC.

Dr Gopal on the Advantages and Potential Benefit of Belzutifan in RCC

February 27th 2024

Nikhil A. Gopal, MD, discusses the benefit of belzutifan for patients with renal cell carcinoma.

Dr Merchan on Key Data Supporting Pembrolizumab-Based Regimens in Advanced RCC

February 27th 2024

Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.

Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer

February 26th 2024

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)

February 26th 2024

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

February 23rd 2024

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

First-Line Treatments for Advanced Clear Cell RCC

February 23rd 2024

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Dr Rini on the Background of the FDA Approval of Belzutifan in RCC

February 21st 2024

Brian I. Rini, MD, FASCO, discusses the research that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

State of the Science Summit - Bladder Cancer & RCC: Chaired by Bradley Somer, MD

February 21st 2024

State of the Science Summit - Bladder Cancer & RCC: Chaired by Bradley Somer, MD

Dr Beckermann on the Investigation of PY314 Plus Pembrolizumab in ccRCC

February 20th 2024

Kathryn Beckermann, MD, PhD, discusses the treatment of PY314 in combination with pembrolizumab in patients with clear cell renal cell carcinoma.

Dr Dondossola on the Importance of Studying Bone Metastasis in RCC

February 19th 2024

Eleonora Dondossola, PhD, discusses the importance of studying bone metastasis in RCC and other genitourinary cancers.

Dr Zhang on the Implications of Findings From the KEYNOTE-564 Trial in RCC

February 14th 2024

Tian Zhang, MD, MHS, discusses the implications of subgroup analyses from the KEYNOTE-564 trial in patients with renal cell carcinoma.